To include your compound in the COVID-19 Resource Center, submit it here.

Top-line data for ofatumumab in second-line lymphoma

Genmab A/S (CSE:GEN) said ofatumumab plus salvage chemotherapy led to an overall response rate

Read the full 147 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE